Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target?
- PMID: 33616998
- DOI: 10.1111/apt.16219
Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target?
Comment in
-
Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target? Authors' reply.Aliment Pharmacol Ther. 2021 Feb;53(4):559-560. doi: 10.1111/apt.16234. Aliment Pharmacol Ther. 2021. PMID: 33616986 No abstract available.
Comment on
-
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.Aliment Pharmacol Ther. 2021 Jan;53(2):314-320. doi: 10.1111/apt.16172. Epub 2020 Nov 21. Aliment Pharmacol Ther. 2021. PMID: 33222190 Free PMC article.
References
REFERENCES
-
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease‐Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73‐84.
-
- European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). J Hepatol. EASL‐EASD‐EASO Clinical Practice Guidelines for the management of non‐alcoholic fatty liver disease. 2016;64:1388‐1402.
-
- Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004. Published 2016 Jan 28.
-
- Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68:2577‐2584.
-
- Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542‐552.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical